Aerpio Announces Publication of Data on Tie2 Activator, AKB-9778, Supporting Future Clinical Development in Cancer
8/5/2013 9:39:45 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that collaborators from Massachusetts General Hospital, Harvard Medical School, New York University and the Massachusetts Institute of Technology published data on Tie2 activator, AKB-9778, in the Journal of the National Cancer Institute. The data highlight clinically relevant changes to tumor vasculature upon administration of AKB-9778 in preclinical models of breast cancer, which delayed tumor growth, slowed metastatic progression and enhanced responses to radiotherapy. AKB-9778 is a first-in-class inhibitor of VE-PTP (vascular endothelial - protein tyrosine phosphatase also known as human protein tyrosine phosphatase beta [HPTPß]) that works to activate Tie2, a receptor on vascular endothelial cells that stabilizes blood vessels, preventing abnormal blood vessel growth and vascular leak.
Help employers find you! Check out all the jobs and post your resume.
comments powered by